Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277914 · ClinicalTrials.gov registry record · Phase 3
Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women
A Phase 3 study, sponsored by Sprout Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 749
- Enrollment target
NCT00277914: Completed Phase 3 study, sponsored by Sprout Pharmaceuticals.
NCT00277914 is a Phase 3 study that has completed, run by Sprout Pharmaceuticals. The registered enrollment target is 749 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00277914, a Phase 3 study, has completed, sponsored by Sprout Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 749 participants
- Enrollment target
Study Summary
To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.
Interventions
- DRUG Flibanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 749 participants |
| Start Date | 2006-01 |
| Phase | Phase 3 |
What the finished NCT00277914 record still lists
NCT00277914 is an interventional study that assigns participants to a tested intervention. The registered 749 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Flibanserin is the first listed.
NCT00277914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00277914 about?
NCT00277914 is a clinical study titled "Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women". To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.
What is the current status of trial NCT00277914?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 749 participants. The study started on 2006-01.
What interventions are being tested in trial NCT00277914?
The interventions under investigation include: Flibanserin (DRUG).
Who is sponsoring clinical trial NCT00277914?
This trial is sponsored by Sprout Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00277914's enrollment target sits among peer trials
749 472nd of 2000 higher than 1,529 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia